Details for Patent: 12,478,619
Which drugs does patent 12,478,619 protect, and when does it expire?
Patent 12,478,619 protects BYSANTI and is included in one NDA.
This patent has eight patent family members in eight countries.
Summary for Patent: 12,478,619
| Title: | Method of treatment with milsaperidone |
| Abstract: | Described herein is an improved method of treatment with iloperidone or milsaperidone, of a patient in need of such treatment, comprising accounting for an increase in a serum urate level of the patient during treatment with the iloperidone or milsaperidone. |
| Inventor(s): | Mihael H. Polymeropoulos |
| Assignee: | Vanda Pharmaceuticals Inc |
| Application Number: | US18/965,591 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 12,478,619
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | BYSANTI | milsaperidone | TABLET;ORAL | 220358-001 | Feb 20, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN ADULTS BY REDUCING A POSSIBILITY OF AN ADVERSE CONSEQUENCE RESULTING FROM AN INCREASE IN A SERUM URATE LEVEL IN A PATIENT | ⤷ Start Trial | ||||
| Vanda Pharms Inc | BYSANTI | milsaperidone | TABLET;ORAL | 220358-001 | Feb 20, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | METHOD FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY REDUCING A POSSIBILITY OF AN ADVERSE CONSEQUENCE RESULTING FROM AN INCREASE IN A SERUM URATE LEVEL IN A PATIENT | ⤷ Start Trial | ||||
| Vanda Pharms Inc | BYSANTI | milsaperidone | TABLET;ORAL | 220358-002 | Feb 20, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | METHOD FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY REDUCING A POSSIBILITY OF AN ADVERSE CONSEQUENCE RESULTING FROM AN INCREASE IN A SERUM URATE LEVEL IN A PATIENT | ⤷ Start Trial | ||||
| Vanda Pharms Inc | BYSANTI | milsaperidone | TABLET;ORAL | 220358-002 | Feb 20, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | METHOD FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN ADULTS BY REDUCING A POSSIBILITY OF AN ADVERSE CONSEQUENCE RESULTING FROM AN INCREASE IN A SERUM URATE LEVEL IN A PATIENT | ⤷ Start Trial | ||||
| Vanda Pharms Inc | BYSANTI | milsaperidone | TABLET;ORAL | 220358-003 | Feb 20, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | METHOD FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY REDUCING A POSSIBILITY OF AN ADVERSE CONSEQUENCE RESULTING FROM AN INCREASE IN A SERUM URATE LEVEL IN A PATIENT | ⤷ Start Trial | ||||
| Vanda Pharms Inc | BYSANTI | milsaperidone | TABLET;ORAL | 220358-003 | Feb 20, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | METHOD FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN ADULTS BY REDUCING A POSSIBILITY OF AN ADVERSE CONSEQUENCE RESULTING FROM AN INCREASE IN A SERUM URATE LEVEL IN A PATIENT | ⤷ Start Trial | ||||
| Vanda Pharms Inc | BYSANTI | milsaperidone | TABLET;ORAL | 220358-004 | Feb 20, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | METHOD FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY REDUCING A POSSIBILITY OF AN ADVERSE CONSEQUENCE RESULTING FROM AN INCREASE IN A SERUM URATE LEVEL IN A PATIENT | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,478,619
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2024278999 | ⤷ Start Trial | |||
| China | 121218989 | ⤷ Start Trial | |||
| European Patent Office | 4687899 | ⤷ Start Trial | |||
| Israel | 324466 | ⤷ Start Trial | |||
| Japan | 2026519236 | ⤷ Start Trial | |||
| South Korea | 20260019503 | ⤷ Start Trial | |||
| Mexico | 2025014073 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
